Prediction of Adverse Outcomes among Women in the Third Trimester of Pregnancy with Coronavirus Disease 2019
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: This study aimed to compare the clinical and laboratory characteristics of two groups of women (favorable and adverse outcome groups) in the third trimester of pregnancy with coronavirus disease 2019 (COVID-19) and to investigate the predictors of specific adverse outcomes. Materials and methods: We retrospectively reviewed the medical records of patients hospitalized with COVID-19 between November 2020 and October 2021 at Kyungpook National University Chilgok Hospital. Adverse outcomes were clinically defined using the Novel Coronavirus Pneumonia Emergency Response Epidemiology Team criteria. The group without adverse outcomes was defined as the "favorable outcome" group and the rest as the "adverse outcome" group. We compared the clinical characteristics between the two groups and examined the correlation between their laboratory results and adverse outcomes. Results: Of the 70 pregnant women included, 37 were in their third trimester. No significant differences in clinical characteristics, except the length of hospitalization, were noted between the groups. In laboratory tests conducted immediately after hospitalization, C-reactive protein (CRP) (1.0 [0.3 - 1.4] vs. 2.3 [1.3 - 3.6], P = 0.001) and ferritin (25.0 [14.5 - 34.5] vs. 53.1 [36.0 - 98.0], P <0.03) levels were significantly different between the groups. Logistic regression analysis revealed that CRP (odds ratio [OR]: 2.26; 95% confidence interval [CI]: 1.09 - 5.51, P = 0.040) and ferritin (OR: 1.06; 95% CI: 1.01 - 1.15, P = 0.047) levels were predictors of adverse outcomes. Conclusion: CRP and ferritin levels are associated with poor prognosis and can predict adverse outcomes in women with COVID-19 in the third trimester of pregnancy.
Abstract
Background: This study aimed to compare the clinical and laboratory characteristics of two groups of women (favorable and adverse outcome groups) in the third trimester of pregnancy with coronavirus disease 2019 (COVID-19) and to investigate the predictors of specific adverse outcomes. Materials and methods: We retrospectively reviewed the medical records of patients hospitalized with COVID-19 between November 2020 and October 2021 at Kyungpook National University Chilgok Hospital. Adverse outcomes were clinically defined using the Novel Coronavirus Pneumonia Emergency Response Epidemiology Team criteria. The group without adverse outcomes was defined as the "favorable outcome" group and the rest as the "adverse outcome" group. We compared the clinical characteristics between the two groups and examined the correlation between their laboratory results and adverse outcomes. Results: Of the 70 pregnant women included, 37 were in their third trimester. No significant differences in clinical characteristics, except the length of hospitalization, were noted between the groups. In laboratory tests conducted immediately after hospitalization, C-reactive protein (CRP) (1.0 [0.3 - 1.4] vs. 2.3 [1.3 - 3.6], P = 0.001) and ferritin (25.0 [14.5 - 34.5] vs. 53.1 [36.0 - 98.0], P <0.03) levels were significantly different between the groups. Logistic regression analysis revealed that CRP (odds ratio [OR]: 2.26; 95% confidence interval [CI]: 1.09 - 5.51, P = 0.040) and ferritin (OR: 1.06; 95% CI: 1.01 - 1.15, P = 0.047) levels were predictors of adverse outcomes. Conclusion: CRP and ferritin levels are associated with poor prognosis and can predict adverse outcomes in women with COVID-19 in the third trimester of pregnancy.
참고문헌 (32)
- Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
- Chen H, "Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women : a retrospective review of medical records", Lancet, 395, pp.809~815 (2020)
- Ellington S, "Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2infection by pregnancy status-United States, January 22-June 7, 2020", MMWR Morb Mortal Wkly Rep, 69, pp.769~775 (2020)
- Zambrano LD, "Update : Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status-United States, January 22-October 3, 2020", MMWR Morb Mortal Wkly Rep, 69, pp.1641~1647 (2020)
- Jamieson DJ, "An update on COVID-19 and pregnancy", Am J Obstet Gynecol, 226, pp.177~186 (2022)
- Collin J, "Public Health Agency of Sweden’s brief report : pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden", Acta Obstet Gynecol Scand, 99, pp.819~822 (2020)
- Allotey J, "Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis", BMJ, 370, pp.m3320~ (2020)
- Santa S, "Paradox of COVID-19 in pregnancy : are pregnant women more protected against or at elevated risk of severe COVID-19?", Future Microbiol, 17, pp.803~812 (2022)
- Di Martino D, "Assessing risk factors for severe forms of COVID-19 in a pregnant population : A clinical series from Lombardy, Italy", Int J Gynaecol Obstet, 152, pp.275~277 (2021)
- Panagiotakopoulos L, "SARS-CoV-2infection among hospitalized pregnant women : reasons for admission and pregnancy characteristics-Eight U. S. Health Care Centers, March 1-May 30, 2020", MMWR Morb Mortal Wkly Rep, 69, pp.1355~1359 (2020)
- Oakes MC, "Pregnancy as a risk factor for severe coronavirus disease 2019 using standardized clinical criteria", Am J Obstet Gynecol MFM, 3, pp.100319~ (2021)
- Rasmussen SA, "Effects of influenza on pregnant women and infants", Am J Obstet Gynecol, 207(3 Suppl), pp.S3~S8 (2012)
- Schwartz DA, "An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternalfetal transmission of SARS-CoV-2 : maternal coronavirus infections and pregnancy outcomes", Arch Pathol Lab Med, 144, pp.799~805 (2020)
- Cartwright JE, "Remodelling at the maternal-fetal interface : relevance to human pregnancy disorders", Reproduction, 140, pp.803~813 (2010)
- Tan EK, "Alterations in physiology and anatomy during pregnancy", Best Pract Res Clin Obstet Gynaecol, 27, pp.791~802 (2013)
- Schwartz DA, "Potential maternal and infant outcomes from(Wuhan)coronavirus 2019-nCoV infecting pregnant women : lessons from SARS, MERS, and other human coronavirus infections", Viruses, 12, pp.194~ (2020)
- Mor G, "The immune system in pregnancy : a unique complexity", Am J Reprod Immunol, 63, pp.425~433 (2010)
- Jamieson DJ, "Emerging infections and pregnancy", Emerg Infect Dis, 12, pp.1638~1643 (2006)
- Silasi M, "Viral infections during pregnancy", Am J Reprod Immunol, 73, pp.199~213 (2015)
- Mullins E, "Pregnancy and neonatal outcomes of COVID-19 : coreporting of common outcomes from PAN-COVID and AAP-SONPM registries", Ultrasound Obstet Gynecol, 57, pp.573~581 (2021)
- Hong Shin Hee, "Clinical Characteristics and Pregnancy-Related Outcomes of Pregnant Women Hospitalized with COVID-19 During the Delta Wave: A Single-Center Observational Study", Infection and Chemotherapy, 54(3), pp.433~445 (2022), 대한감염학회[DOI]
- Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descriptive study", Lancet, 395, pp.507~513 (2020)
- Wang Z, "Clinical characteristics and laboratory results of pregnant women with COVID-19 in Wuhan, China", Int J Gynaecol Obstet, 150, pp.312~317 (2020)
- Zeng F, "Association of inflammatory markers with the severity of COVID-19 : a meta-analysis", Int J Infect Dis, 96, pp.467~474 (2020)
- Feld J, "Ferritin levels in patients with COVID-19 : a poor predictor of mortality and hemophagocytic lymphohistiocytosis", Int J Lab Hematol, 42, pp.773~779 (2020)
- Perricone C, "COVID-19 as part of the hyperferritinemic syndromes : the role of iron depletion therapy", Immunol Res, 68, pp.213~224 (2020)
- Li Y, "Retrospective analysis of laboratory testing in 54 patients with severe-or criticaltype 2019 novel coronavirus pneumonia", Lab Invest, 100, pp.794~800 (2020)
- Torti FM, "Regulation of ferritin genes and protein", Blood, 99, pp.3505~3516 (2002)
- Cheng L, "Ferritin in the coronavirus disease 2019(COVID-19) : a systematic review and meta-analysis", J Clin Lab Anal, 34, pp.e23618~ (2020)
- Para O, "Ferritin as prognostic marker in COVID-19 : the FerVid study", Postgrad Med, 134, pp.58~63 (2022)
- Bennett TD, "Very high serum ferritin levels are associated with increased mortality and critical care in pediatric patients", Pediatr Crit Care Med, 12, pp.e233~e236 (2011)
- Cui X, "A systematic review and meta-analysis of children with coronavirus disease 2019(COVID-19)", J Med Virol, 93, pp.1057~1069 (2021)